Leerink Partners analyst Jim Kelly reiterated a Hold rating on Cigna (CI – Research Report) on October 8. The company's shares closed last Monday at $203.93. According to TipRanks.com, Kelly is a 1-star analyst with an average return of -1.7% and a 27.3% success rate. Kelly covers the Healthcare sector, focusing on stocks such as Enanta Pharmaceuticals, Atea Pharmaceuticals, and Aligos Therapeutics. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Cigna with a $267.53 average price target. See today’s analyst top recommended stocks >> The company has a one-year high of $272.81 and a one-year low of $160.37. Currently, Cigna has an average volume of 2.02M. Based on the recent corporate insider activity of 115 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of CI in relation to earlier this year. TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities. Founded in 1792, Cigna Corporation is a Connecticut-based global health services company, which provides insurance and related products and services. It operates through the following segments: Health Services, Integrated Medical, International Markets, and Group Disability and Other. Read More on CI: Analysts’ Opinions Are Mixed on These Services Stocks: Universal Music Group (OtherUMGNF) and AMC Entertainment (AMC) Analysts Are Bullish on Top Conglomerates Stocks: Oshkosh (OSK), Beacon Roofing Supply (BECN) Analysts Offer Insights on Materials Companies: and Freeman Gold Corp. (FMANF) Analysts Are Bullish on These Healthcare Stocks: Sarepta Therapeutics (SRPT), Dice Therapeutics Inc (DICE) Analysts’ Top Conglomerates Picks: NEL ASA (NLLSF)